Analysis leveraging USP’s Medicine Supply Map suggests many of the essential cancer medicines have inherently vulnerable supply chains and are at greater risk for shortage compared to other generic medicines ..read more

This year has seen a flurry of activity by the U.S. Food and Drug Administration surrounding ophthalmic products ..read more

Understanding the landscape to expand, strengthen, and diversify African-based manufacturing ..read more

Understanding the landscape to expand, strengthen, and diversify African-based manufacturing ..read more

In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy ..read more

Patient access to cancer drugs can mean the difference between life and death. Persistent shortages threaten patients’ access to the lifesaving and life-sustaining therapies they need ..read more

This year has seen a flurry of activity by the U.S. Food and Drug Administration surrounding ophthalmic products ..read more

Advanced manufacturing technologies such as pharmaceutical continuous manufacturing (PCM) are gaining increasing stakeholder interest for their potential to improve global health by bolstering medicines supply chain resilience ..read more

The frightening words, “you have cancer”, will be heard by approximately 2 million people in the U.S. this year alone ..read more

The U.S. Pharmacopeia (USP) has long been recognized as an international leader in medicines quality and supply chain integrity ..read more